Insulin Glargine,hum.Rec.Anlog
Brand name: Lantus Solostar
Rank #8 of 500 drugs by total cost
$1.94B
Total Cost
3,118,259
Total Claims
$1.94B
Total Cost
95,669
Prescribers
$622
Cost per Claim
452,927
Beneficiaries
5,459,707
30-Day Fills
$20K
Avg Cost/Provider
33
Avg Claims/Provider
About Insulin Glargine,hum.Rec.Anlog
Insulin Glargine,hum.Rec.Anlog (sold as Lantus Solostar) was prescribed 3,118,259 times by 95,669 Medicare Part D providers in 2023, costing the program $1.94B. At $622 per claim, this is a high-cost medication.
💰 This drug alone accounts for 0.7% of all Medicare Part D drug spending.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 5 | Rivaroxaban (Xarelto) | $2.45B | 2,628,123 |
| 6 | Adalimumab (Humira(Cf) Pen) | $2.17B | 240,925 |
| 7 | Lenalidomide (Revlimid) | $2.15B | 130,834 |
| 8 | Insulin Glargine,hum.Rec.Anlog (Lantus Solostar) | $1.94B | 3,118,259 |
| 9 | Fluticasone/Umeclidin/Vilanter (Trelegy Ellipta) | $1.81B | 2,046,216 |
| 10 | Dapagliflozin Propanediol (Farxiga) | $1.65B | 1,666,200 |
| 11 | Sitagliptin Phosphate (Januvia) | $1.54B | 1,567,668 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology